PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN TREATMENT WITH BVD (BENDAMUSTINE BORTEZOMIB-DEXAMETHASONE)

被引：0
|
作者：
Cerchione, C. [1 ]
Nappi, D. [1 ]
Salvatore, D. [1 ]
Migliaccio, I. [1 ]
Pane, F. [1 ]
Catalano, L. [1 ]
机构：
[1] Au Federico Ii, Hematol Ematol & Trapianto, Naples, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1330
引用
收藏
页码：550 / 551
页数：2
相关论文
共 50 条
  • [31] Escalation treatment algorithm with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma: A singel centre experience.
    Fenk, Roland
    Michael, Mark
    Zohren, Fabian
    Graef, Thorsten
    Czibere, Arkosch
    Balleisen, Sebastian
    Neumann, Frank
    Rohr, Ulrich-Peter
    Steidl, Ulrich
    Haas, Rainer
    Kobbe, Guido
    BLOOD, 2006, 108 (11) : 1010A - 1010A
  • [32] Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated
    Ludwig, Heinz
    Kasparu, Hedwig
    Greil, Richard
    Leitgeb, Clemens
    Muelduer, Ercan
    Rauch, Elisabeth
    Zojer, Niklas
    Autzinger, Eva Maria
    Linkesch, Werner
    Kuhr, Thomas
    Pour, Ludek
    Adam, Zdenek
    BLOOD, 2012, 120 (21)
  • [33] BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA : THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM) 2009-01 PROTOCOL
    Rodon, P.
    Hulin, C.
    Pegourie, B.
    Tiab, M.
    Anglaret, B.
    Benboubker, L.
    Jardel, H.
    Decaux, O.
    Kolb, B.
    Roussel, M.
    Garderet, L.
    Leleu, X.
    Royer, B.
    Banos, A.
    Benramdane, R.
    Cony-Makhoul, P.
    Dib, M.
    Fontan, J.
    Stoppa, A.
    Traulle, C.
    Vilque, J.
    Moreau, P.
    Mathiot, C.
    Avet-Loiseau, H.
    HAEMATOLOGICA, 2012, 97 : 342 - 342
  • [34] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
  • [36] Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
    Chng, W-J
    Goldschmidt, H.
    Dimopoulos, M. A.
    Moreau, P.
    Joshua, D.
    Palumbo, A.
    Facon, T.
    Ludwig, H.
    Pour, L.
    Niesvizky, R.
    Oriol, A.
    Rosinol, L.
    Suvorov, A.
    Gaidano, G.
    Pika, T.
    Weisel, K.
    Goranova-Marinova, V.
    Gillenwater, H. H.
    Mohamed, N.
    Feng, S.
    Aggarwal, S.
    Hajek, R.
    LEUKEMIA, 2017, 31 (06) : 1368 - 1374
  • [37] Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
    Heinz Ludwig
    Philippe Moreau
    Meletios A. Dimopoulos
    Maria-Victoria Mateos
    Martin Kaiser
    Roman Hajek
    Shibao Feng
    Kim Cocks
    Jaqueline Buchanan
    Katja Weisel
    Blood Cancer Journal, 9
  • [38] Combination chemotherapy with bortezomib, bendamustine and prednisone for patients with refractory/relapsed multiple myeloma:: An unicentric retrospective trial
    Poenisch, W.
    Bourgeois, M.
    Wang, S. Y.
    Heyn, S.
    Jaekel, N.
    Braunert, L.
    Pfannes, R.
    Nehring, C.
    Nehring, C.
    Becker, C.
    Becker, C.
    Al Ali, H.
    Hensel, G.
    Niederwieser, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 432 - 432
  • [39] Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
    Ludwig, Heinz
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Mateos, Maria-Victoria
    Kaiser, Martin
    Hajek, Roman
    Feng, Shibao
    Cocks, Kim
    Buchanan, Jaqueline
    Weisel, Katja
    BLOOD CANCER JOURNAL, 2019, 9 (3)
  • [40] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
12345